Literature DB >> 35171365

Altered levels of circulating CD8+CXCR5+PD-1+T follicular cytotoxic cells in primary Sjögren's syndrome.

Xuwen Zhai1, Yanlin Wang2, Hui Guo3,4, Zhaojun Liang2, Min Feng2, Yanyao Wu2, Yan Qin2, Xiangcong Zhao2, Chong Gao5, Jing Luo6.   

Abstract

BACKGROUND: Circulating CD8+ T-cells expressing the C-X-C chemokine receptor type 5 (CXCR5) (CD8+CXCR5+T), a recently identified follicular cytotoxic T cell subset, are involved in antiviral immunity and autoimmunity, but their abundance and role in the pathogenesis of primary Sjögren syndrome (pSS) are unknown.
METHODS: Circulating CD8+CXCR5+T cell and CD8+ regulatory T cells (CD8+Treg) were evaluated in 49 pSS patients (19 patients with pulmonary involvement) and 24 age- and sex-matched healthy controls (HCs) by flow cytometry. Orthogonal partial least squares discriminant analysis (OPLS-DA) was performed, and receiver operating characteristic curves (ROC) were generated to identify characteristic cell subsets. Spearman's correlation analysis was conducted to examine the relationships between CD8+ T cell subsets and clinical features.
RESULTS: The proportions and numbers of CD8+CXCR5+, CD8 + CXCR5+ programmed death 1-positive (PD-1+), and CD8+CXCR5-PD-1+T cells were significantly higher, whereas those of CD8+Treg were markedly lower, in pSS patients than HCs. The CD8+CXCR5+PD-1+T cell to CD8+Treg ratio had the greatest discriminatory power for pSS and HCs according to OPLS-DA and ROC analyses. The increased numbers of CD8+CXCR5+T cells and CD8+CXCR5+PD-1+T cells were strongly associated with those of CD4+CXCR5+T and B cells. The proportions and numbers of CD8+CXCR5+PD-1+T cells were increased in pSS patients with lung involvement.
CONCLUSIONS: We identified a new CD8+CXCR5+PD-1+T subset, which was increased in abundance in pSS patients, particularly those with lung involvement, compared with HCs. Also, the CD8+CXCR5+PD-1+T to CD8+Treg ratio may be useful for identifying pSS. Our findings suggest that targeting follicular CD8+T cell subsets has therapeutic potential for pSS. Key Points • CD8+CXCR5+ T cells were expanded in the circulation of patients with pSS. • Reduced numbers CD8+Treg cells in pSS patients. • Increased CD8+CXCR5+PD-1+T cells in pSS patients with pulmonary involvement.
© 2022. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  CD8+ regulatory T cells; CD8+CXCR5+ follicular cytotoxic T subsets; Lung involvement; OPLS-DA; Primary Sjögren’s syndrome

Mesh:

Substances:

Year:  2022        PMID: 35171365     DOI: 10.1007/s10067-022-06098-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

Review 1.  Specific control of immunity by regulatory CD8 T cells.

Authors:  Xiao Lei Tang; Trevor Rf Smith; Vipin Kumar
Journal:  Cell Mol Immunol       Date:  2005-02       Impact factor: 11.530

Review 2.  T follicular helper cells in human autoimmunity.

Authors:  Hideki Ueno
Journal:  Curr Opin Immunol       Date:  2016-08-30       Impact factor: 7.486

3.  The Ratio of Blood T Follicular Regulatory Cells to T Follicular Helper Cells Marks Ectopic Lymphoid Structure Formation While Activated Follicular Helper T Cells Indicate Disease Activity in Primary Sjögren's Syndrome.

Authors:  Valter R Fonseca; Vasco C Romão; Ana Agua-Doce; Mara Santos; Dolores López-Presa; Ana Cristina Ferreira; João Eurico Fonseca; Luis Graca
Journal:  Arthritis Rheumatol       Date:  2018-03-25       Impact factor: 10.995

Review 4.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

5.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Authors:  Se Jin Im; Masao Hashimoto; Michael Y Gerner; Junghwa Lee; Haydn T Kissick; Matheus C Burger; Qiang Shan; J Scott Hale; Judong Lee; Tahseen H Nasti; Arlene H Sharpe; Gordon J Freeman; Ronald N Germain; Helder I Nakaya; Hai-Hui Xue; Rafi Ahmed
Journal:  Nature       Date:  2016-08-02       Impact factor: 49.962

6.  CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas.

Authors:  Kieu-Suong Le; Patricia Amé-Thomas; Karin Tarte; Françoise Gondois-Rey; Samuel Granjeaud; Florence Orlanducci; Etienne D Foucher; Florence Broussais; Reda Bouabdallah; Thierry Fest; Dominique Leroux; Sapna Yadavilli; Patrick A Mayes; Luc Xerri; Daniel Olive
Journal:  Blood Adv       Date:  2018-08-14

7.  CXCR5+ CD8+ T cells potently infiltrate pancreatic tumors and present high functionality.

Authors:  Minghui Bai; Youwei Zheng; Haichao Liu; Baowei Su; Yong Zhan; Hua He
Journal:  Exp Cell Res       Date:  2017-09-28       Impact factor: 3.905

8.  CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis.

Authors:  Young Mo Kang; Xiaoyu Zhang; Ulf G Wagner; Hongyu Yang; Robert D Beckenbaugh; Paul J Kurtin; Jörg J Goronzy; Cornelia M Weyand
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

9.  The transcription factor Runx3 guards cytotoxic CD8+ effector T cells against deviation towards follicular helper T cell lineage.

Authors:  Qiang Shan; Zhouhao Zeng; Shaojun Xing; Fengyin Li; Stacey M Hartwig; Jodi A Gullicksrud; Samarchith P Kurup; Natalija Van Braeckel-Budimir; Yao Su; Matthew D Martin; Steven M Varga; Ichiro Taniuchi; John T Harty; Weiqun Peng; Vladimir P Badovinac; Hai-Hui Xue
Journal:  Nat Immunol       Date:  2017-06-12       Impact factor: 25.606

10.  CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance.

Authors:  Yuhong Chen; Mei Yu; Yongwei Zheng; Guoping Fu; Gang Xin; Wen Zhu; Lan Luo; Robert Burns; Quan-Zhen Li; Alexander L Dent; Nan Zhu; Weiguo Cui; Laurent Malherbe; Renren Wen; Demin Wang
Journal:  Nat Commun       Date:  2019-09-27       Impact factor: 14.919

View more
  1 in total

1.  CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions.

Authors:  Kosuke Murayama; Ippei Ikegami; Ryuta Kamekura; Hiroshi Sakamoto; Masahiro Yanagi; Shiori Kamiya; Taiki Sato; Akinori Sato; Katsunori Shigehara; Motohisa Yamamoto; Hiroki Takahashi; Ken-Ichi Takano; Shingo Ichimiya
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.